Metastatic breast cancer: Overview of treatment

Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Ne...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical orthopaedics and related research 2003-10, Vol.415 (415), p.S132-S137
Hauptverfasser:	ALI, S. M, HARVEY, H. A, LIPTON, Allan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Bone Neoplasms - drug therapy Bone Neoplasms - secondary Breast Neoplasms - drug therapy Breast Neoplasms - pathology Diseases of the osteoarticular system Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Prognosis Tamoxifen - therapeutic use Trastuzumab Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.
ISSN:	0009-921X 1528-1132
DOI:	10.1097/01.blo.0000092981.12414.7b